Is colistin a last-resort antibiotic?

Yes, colistin is typically reserved for serious infections caused by multidrug-resistant gram-negative bacteria when standard antibiotics have failed. Its mechanism is highly effective, but because it's potent and can have side effects, it's not a first-line therapy. However, its central role in treating resistant infections makes it a cornerstone of modern infection control in hospitals.

Why doesn't colistin work against gram-positive bacteria?

Colistin's mechanism depends on binding to lipopolysaccharides in the outer membrane—a structure that only gram-negative bacteria have. Gram-positive bacteria have a thick peptidoglycan layer instead, so colistin cannot bind and disrupt it. This is why colistin is gram-negative specific.

How quickly does colistin kill bacteria?

Colistin exhibits rapid bactericidal activity—meaning it actively kills bacteria rather than just stopping their growth. Studies show significant bacterial reduction within hours of exposure, especially at higher concentrations. The speed depends on colistin concentration at the infection site and the specific bacterial species.

Can bacteria develop resistance to colistin?

Yes, resistance can develop, but it's relatively rare compared to other antibiotics. Bacteria develop colistin resistance through mutations that alter their LPS layer charge or composition. However, these mutations often come with fitness costs, which is why colistin resistance hasn't become widespread despite decades of use.

What's the difference between colistin and other peptide antibiotics?

Colistin disrupts bacterial cell membranes by binding to LPS, while other peptide antibiotics like bacitracin work through different mechanisms—bacitracin inhibits cell wall synthesis instead. Each peptide antibiotic targets a different bacterial vulnerability, allowing clinicians to select the most appropriate option based on the pathogen.

How Does Colistin Work? Mechanism & Action

Colistin is an FDA-approved antibiotic that works by disrupting the outer cell membranes of gram-negative bacteria, causing them to leak and die. It's a polypeptide antibiotic—meaning it's made of amino acids—that binds to the lipopolysaccharide (LPS) layer of bacterial cell walls, fundamentally destabilizing their structural integrity. Originally developed in the 1950s and now experiencing a clinical resurgence, colistin has become a critical tool against multidrug-resistant pathogens like Pseudomonas aeruginosa and Acinetobacter baumannii, especially when other antibiotics fail. Over 119 clinical trials have investigated its efficacy and safety across different patient populations and infection types.

The Bacterial Cell Membrane: Colistin's Target

To understand how colistin works, you need to know what it's attacking. Gram-negative bacteria have a unique outer membrane composed of lipopolysaccharides (LPS)—complex molecules that make these bacteria both structurally tough and inherently resistant to many antibiotics. This outer membrane is like a fortress wall that conventional antibiotics can't easily penetrate.

Colistin is a cationic (positively charged) peptide antibiotic that disrupts this LPS layer by electrostatic interaction. The positive charge on colistin molecules allows them to bind directly to the negatively charged LPS molecules on the bacterial surface. This binding is the critical first step in colistin's mechanism of action.

Membrane Disruption and Bacterial Cell Death

Once colistin binds to the LPS layer, it doesn't just sit there—it actively destabilizes the entire outer membrane structure. Research shows that colistin insertion into the membrane increases permeability, causing the membrane to become leaky. This is catastrophic for the bacterium because the outer membrane is meant to be a selective barrier. When colistin breaches this barrier, intracellular contents leak out, ions escape, and the cell loses homeostasis.

The mechanism involves both detergent-like activity (disrupting lipid bilayers) and direct protein-membrane interactions that destabilize key structural components. Multiple studies using electron microscopy have documented the morphological changes that occur in bacterial cells exposed to colistin—cell wall degradation, membrane blebbing, and eventual cell lysis (breaking open).

Why Colistin Works Against Resistant Bacteria

One reason colistin has become so valuable in modern medicine is that many bacteria haven't developed widespread resistance to it, even after decades of clinical use. This is partly because the mechanism—directly targeting a fundamental structural component of the cell membrane—is difficult for bacteria to evolve around. Resistance would require changing the charge or composition of the LPS layer itself, which would compromise the bacterium's own survival.

Colistin is particularly effective against Pseudomonas aeruginosa and Acinetobacter baumannii, two notoriously difficult-to-treat gram-negative pathogens. A comprehensive review of clinical data showed that colistin retains activity against 90%+ of multidrug-resistant gram-negative isolates, making it a last-resort option when standard antibiotics fail.

Pharmacokinetics: How Colistin Gets Around Your Body

Understanding colistin's mechanism isn't just about what happens at the bacterial level—it's also about how the drug reaches infections. Colistin is a polypeptide, which means it's vulnerable to stomach acid and digestive enzymes. That's why it's typically given intravenously (IV) for systemic infections, though it can be inhaled directly into the lungs for respiratory infections caused by resistant bacteria.

Once in the bloodstream, colistin distributes to infected tissues and achieves high concentrations at infection sites. Studies indicate that achieving adequate drug concentrations at the site of infection is critical for microbial killing. The drug's mechanism is concentration-dependent, meaning higher colistin levels kill bacteria more rapidly.

Clinical Evidence and Real-World Efficacy

The FDA approved colistin because clinical trials demonstrated its effectiveness in treating serious infections caused by gram-negative bacteria resistant to other antibiotics. With over 119 registered clinical trials investigating colistin across various infection types—including ventilator-associated pneumonia, urinary tract infections, and bloodstream infections—the evidence base continues to expand.

Colistin is now a cornerstone therapy in infection control protocols, particularly in intensive care units where multidrug-resistant gram-negative bacteria are endemic. Its mechanism of action, while aggressive, remains highly relevant because it targets a vulnerability that resistant bacteria haven't yet overcome.

Polypeptide Structure and Antibiotic Activity

Colistin's identity as a polypeptide antibiotic distinguishes it from many other classes of antibiotics. It's composed of amino acids linked in a specific sequence that creates its three-dimensional shape and charge distribution. This polypeptide structure is what gives colistin its ability to interact with bacterial membranes in a way that small-molecule drugs cannot.

Compare this to other antimicrobials like bacitracin, another peptide antibiotic that works differently—bacitracin inhibits cell wall synthesis rather than disrupting the membrane itself. The peptide family of antibiotics offers multiple mechanisms for combating resistant bacteria, with colistin's membrane-targeting approach being uniquely effective against gram-negative organisms.

Regulatory Status and Global Approval

Colistin holds FDA approval in the United States, EMA authorization in Europe, and Health Canada approval, reflecting its validated safety and efficacy profile across jurisdictions. The FDA's approval was based on clinical evidence showing colistin's superiority over placebo and other comparators in treating multidrug-resistant gram-negative infections, cementing its role in modern antimicrobial therapy.

The regulatory pathway for colistin underscores an important principle: sometimes older drugs experience clinical renaissance when resistance patterns change and their unique mechanisms become invaluable.

Limitations and Resistance Considerations

While colistin's mechanism is potent, it's not perfect. Some bacteria—particularly certain strains of Klebsiella pneumoniae and Acinetobacter baumannii—have developed colistin resistance through mutations that alter their LPS structure or through other adaptive mechanisms. Additionally, colistin can have nephrotoxicity (kidney toxicity) in some patients, requiring careful dosing and monitoring.

Yet despite these limitations, colistin remains a critical tool because its mechanism is fundamentally sound and resistance remains relatively rare, especially compared to other antibiotic classes.

How Does Colistin Work? The Mechanism Behind This Powerful Antibiotic